Last reviewed 2026-04-23 · How we verify

KSI-101

KSI-101 is a bispecific antibody that simultaneously targets VEGF and ANG-2 to reduce retinal inflammation and vascular leakage in retinal diseases.

KSI-101 is a bispecific antibody that simultaneously targets VEGF and ANG-2 to reduce retinal inflammation and vascular leakage in retinal diseases. Used for Wet age-related macular degeneration (wAMD), Diabetic retinopathy.

At a glance

Mechanism of action

KSI-101 binds both vascular endothelial growth factor (VEGF) and angiopoietin-2 (ANG-2), two key drivers of retinal vascular dysfunction and inflammation. By blocking both pathways simultaneously, the drug aims to achieve superior anti-inflammatory and anti-vascular permeability effects compared to VEGF inhibition alone, potentially improving outcomes in wet age-related macular degeneration and diabetic retinopathy.

Approved indications

• Wet age-related macular degeneration (wAMD)
• Diabetic retinopathy

Common side effects

• Conjunctival hemorrhage
• Eye pain
• Floaters
• Injection site reactions

Key clinical trials

• A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE (PHASE3)
• A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• KSI-101 CI brief — competitive landscape report
• KSI-101 updates RSS · CI watch RSS
• Kodiak Sciences Inc portfolio CI